---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-145022"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:36:13.021968+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q1 net loss $21.3M; pipeline focus on NUV-422, NUV-868, DDC

## Summary
- Net loss $21.3M ($0.10 per share) vs $20.4M ($0.12) in Q1 2021.
- Cash, cash equivalents and marketable securities $737.7M as of March 31, 2022.
- R&D expenses $20.7M (up $4.8M YoY); G&A $7.5M (up $2.9M YoY).
- On track to initiate Phase 1b combos and Phase 2 monotherapy for NUV-422 by end-2022; first patient dosed in NUV-868 Phase 1.
- Deprioritized early-stage NUV-569 and A2A programs to allocate resources to NUV-422, NUV-868, and DDC program.

## SEC filing metadata
- accession: 0001193125-22-145022
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312522145022/0001193125-22-145022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312522145022/d293509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-145022
- JSON: https://secwatch.observer/filing/0001193125-22-145022.json
- Plain text: https://secwatch.observer/filing/0001193125-22-145022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.